SeQuent secures approvals from NSE and BSE for proposed merger with Viyash Life Sciences

29 May 2025 Evaluate

Sequent Scientific (SeQuent) has secured approvals from both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) for its proposed merger with Hyderabad-based Viyash Life Sciences (Viyash). The company has now filed for clearance with the National Company Law Tribunal (NCLT), marking a crucial milestone in the merger process. Under the agreed terms, shareholders of Viyash will receive 56 SeQuent shares for every 100 Viyash shares held.

The merger will bring together two strong business verticals -- Global Animal Health and a world class API business unlocking access to over 150 countries. The combined entity will benefit from a five-fold increase in R&D talent and a nine-fold expansion in USFDA-approved manufacturing capacity, creating a robust and scalable operating backbone. The company operates in the niche segment of Animal Health and markets its products in 90+ countries. It has built local footprints in Europe, Latin America and emerging markets including India, while Viyash has built a strong presence in API and R&D space with strong business relations with leading companies around the globe.

Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals.

Sequent Scientific Share Price

199.65 -8.00 (-3.85%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×